SG11201811442UA - Formulation of a peptide vaccine - Google Patents
Formulation of a peptide vaccineInfo
- Publication number
- SG11201811442UA SG11201811442UA SG11201811442UA SG11201811442UA SG11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical composition
- pct
- composition
- reconstitution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 2
- 229940023041 peptide vaccine Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16175215 | 2016-06-20 | ||
PCT/EP2017/064882 WO2017220463A1 (fr) | 2016-06-20 | 2017-06-19 | Formulation d'un vaccin peptidique. |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811442UA true SG11201811442UA (en) | 2019-01-30 |
Family
ID=56148213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811442UA SG11201811442UA (en) | 2016-06-20 | 2017-06-19 | Formulation of a peptide vaccine |
Country Status (14)
Country | Link |
---|---|
US (3) | US10702598B2 (fr) |
EP (2) | EP3471758A1 (fr) |
JP (3) | JP7115803B2 (fr) |
KR (2) | KR20230030032A (fr) |
CN (2) | CN109641039B (fr) |
AU (2) | AU2017281389B2 (fr) |
CA (1) | CA3027459A1 (fr) |
EA (1) | EA201990071A1 (fr) |
IL (2) | IL291537B2 (fr) |
MX (2) | MX2018015749A (fr) |
MY (1) | MY189551A (fr) |
SG (1) | SG11201811442UA (fr) |
WO (1) | WO2017220463A1 (fr) |
ZA (1) | ZA202100578B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112016030580B1 (pt) * | 2014-06-26 | 2023-12-19 | The Rockefeller University | Polipeptídeo de lisina e fragmento de polipeptídeo com atividade para matar bactérias gram-negativas |
AU2016235388B2 (en) * | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
CA3062591A1 (fr) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Vecteurs neoantigeniques alphaviraux |
JP2021511054A (ja) * | 2018-01-24 | 2021-05-06 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | Hpv免疫療法 |
EP3796927A4 (fr) * | 2018-05-23 | 2022-04-20 | Gritstone bio, Inc. | Antigènes partagés |
KR20220016137A (ko) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | 변형된 아데노바이러스 |
EP4013771A4 (fr) * | 2019-08-15 | 2023-09-06 | National Institute for Biotechnology in the Negev Ltd. | Peptides d'administration et leurs procédés d'utilisation |
US20230248814A1 (en) * | 2020-06-01 | 2023-08-10 | The Broad Institute, Inc. | Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes |
JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
WO2023285412A1 (fr) | 2021-07-12 | 2023-01-19 | Isa Pharmaceuticals B.V. | Quantification de substance améliorée dans des mélanges complexes |
CN113842455B (zh) * | 2021-08-27 | 2022-05-13 | 北京康乐卫士生物技术股份有限公司 | 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗 |
KR102545000B1 (ko) * | 2021-10-20 | 2023-06-16 | 전옥님 | 그래핀을 이용한 전자파 차폐 시트 |
WO2023143445A1 (fr) * | 2022-01-25 | 2023-08-03 | 厦门大学 | Peptide épitope et anticorps pour traiter une infection par vhb et des maladies associées |
WO2024068636A1 (fr) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Peptides immunogènes à adjuvant pour administration intradermique |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ42894A3 (en) | 1991-08-26 | 1995-02-15 | Scripps Research Inst | Peptides inducing cytotoxic response of t lymphocytes to hepatitis b virus |
US20110097352A9 (en) | 1992-01-29 | 2011-04-28 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
DE69431665T2 (de) | 1993-08-02 | 2003-08-21 | Scripps Research Inst | Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus |
DK1082141T3 (da) | 1998-05-23 | 2005-12-05 | Univ Leiden Medical Ct | CD40-bindende molekyler og CTL-peptider til behandling af tumorer |
US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
DE10059631A1 (de) | 2000-12-01 | 2002-07-18 | Medigene Ag | T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie |
EP2363406B1 (fr) * | 2000-12-08 | 2019-02-27 | Academisch Ziekenhuis Leiden | Peptides longs de 22-45 résidus d'acides aminés induisant et/ou améliorant les réponses immunes spécifiques à des antigènes |
US7202034B2 (en) * | 2000-12-08 | 2007-04-10 | Academisch Ziekenhuis Leiden | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
FR2824326B1 (fr) | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
EP1479761A1 (fr) | 2003-05-21 | 2004-11-24 | PrimaGen Holding B.V. | Nouvel enterovirus, vaccins, médicaments et trousses diagnostiques |
CA2545034C (fr) * | 2003-11-20 | 2013-03-05 | Novo Nordisk A/S | Formulations peptidiques a base de propylene glycol optimales pour la production et l'utilisation dans des dispositifs d'injection |
GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
EP2308467A3 (fr) * | 2005-06-17 | 2011-06-22 | Hospira Australia Pty Ltd | Compositions Pharmaceutiques Liquides de Docétaxel |
CA2996732C (fr) | 2007-03-26 | 2020-10-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptides derives de prame et compositions immunogenes comprenant ceux-ci |
AU2008269721B2 (en) * | 2007-05-31 | 2013-01-10 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Intradermal HPV peptide vaccination |
ES2406077T3 (es) | 2007-05-31 | 2013-06-05 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacuna de péptido p53 |
AU2008257792B2 (en) | 2007-05-31 | 2013-08-29 | Isa Pharmaceuticals B.V. | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
KR20090125629A (ko) | 2008-06-02 | 2009-12-07 | 바이오코아 주식회사 | 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물 |
KR20090125628A (ko) | 2008-06-02 | 2009-12-07 | 바이오코아 주식회사 | 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물 |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
AU2012225268B2 (en) * | 2011-03-10 | 2016-10-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
WO2013006050A1 (fr) | 2011-07-06 | 2013-01-10 | Isa Pharmaceuticals B.V. | Peptides induisant ou renforçant la réponse immunitaire contre l'antigène spécifique de la membrane prostatique (psma) |
NL2007536C2 (en) | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
WO2013113326A1 (fr) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Composition pharmaceutique comprenant un complexe support polymère - charge et au moins un antigène de protéine ou de peptide |
CA2874923C (fr) * | 2012-06-06 | 2021-08-31 | Bionor Immuno As | Peptides issus de proteines virales pour l'utilisation en tant qu'immunogenes et reactifs de dosage |
GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
CN106573960B (zh) | 2014-06-02 | 2021-07-02 | Isa制药有限公司 | 用于针对乙型肝炎病毒感染的治疗性接种的合成长肽(slp) |
-
2017
- 2017-06-19 EP EP17732070.2A patent/EP3471758A1/fr active Pending
- 2017-06-19 EA EA201990071A patent/EA201990071A1/ru unknown
- 2017-06-19 EP EP19174463.0A patent/EP3552623A1/fr active Pending
- 2017-06-19 CA CA3027459A patent/CA3027459A1/fr active Pending
- 2017-06-19 US US16/311,629 patent/US10702598B2/en active Active
- 2017-06-19 KR KR1020237005809A patent/KR20230030032A/ko not_active Application Discontinuation
- 2017-06-19 IL IL291537A patent/IL291537B2/en unknown
- 2017-06-19 CN CN201780051075.4A patent/CN109641039B/zh active Active
- 2017-06-19 AU AU2017281389A patent/AU2017281389B2/en active Active
- 2017-06-19 WO PCT/EP2017/064882 patent/WO2017220463A1/fr unknown
- 2017-06-19 MX MX2018015749A patent/MX2018015749A/es unknown
- 2017-06-19 JP JP2019518137A patent/JP7115803B2/ja active Active
- 2017-06-19 CN CN202310680875.XA patent/CN117018170A/zh active Pending
- 2017-06-19 KR KR1020197001793A patent/KR20190020098A/ko not_active IP Right Cessation
- 2017-06-19 SG SG11201811442UA patent/SG11201811442UA/en unknown
- 2017-06-19 MY MYPI2018002793A patent/MY189551A/en unknown
-
2018
- 2018-12-14 MX MX2023003875A patent/MX2023003875A/es unknown
- 2018-12-20 IL IL263846A patent/IL263846B/en unknown
-
2020
- 2020-06-10 US US16/898,141 patent/US11426458B2/en active Active
-
2021
- 2021-01-27 ZA ZA2021/00578A patent/ZA202100578B/en unknown
-
2022
- 2022-07-22 JP JP2022117117A patent/JP2022141878A/ja active Pending
- 2022-08-24 US US17/894,945 patent/US20230233658A1/en active Pending
-
2024
- 2024-03-05 JP JP2024033045A patent/JP2024069303A/ja active Pending
- 2024-03-28 AU AU2024202005A patent/AU2024202005A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190020098A (ko) | 2019-02-27 |
US20230233658A1 (en) | 2023-07-27 |
IL263846A (en) | 2019-01-31 |
ZA202100578B (en) | 2023-03-29 |
IL291537A (en) | 2022-05-01 |
CA3027459A1 (fr) | 2017-12-28 |
JP2022141878A (ja) | 2022-09-29 |
IL291537B1 (en) | 2023-07-01 |
MX2023003875A (es) | 2023-04-18 |
AU2017281389B2 (en) | 2024-02-22 |
US11426458B2 (en) | 2022-08-30 |
EP3471758A1 (fr) | 2019-04-24 |
WO2017220463A1 (fr) | 2017-12-28 |
CN109641039A (zh) | 2019-04-16 |
MX2018015749A (es) | 2019-06-17 |
MY189551A (en) | 2022-02-16 |
CN117018170A (zh) | 2023-11-10 |
JP2024069303A (ja) | 2024-05-21 |
KR20230030032A (ko) | 2023-03-03 |
IL263846B (en) | 2022-04-01 |
CN109641039B (zh) | 2023-08-04 |
JP7115803B2 (ja) | 2022-08-09 |
IL291537B2 (en) | 2023-11-01 |
AU2024202005A1 (en) | 2024-04-18 |
EP3552623A1 (fr) | 2019-10-16 |
EA201990071A1 (ru) | 2019-06-28 |
US20190231863A1 (en) | 2019-08-01 |
US20200297835A1 (en) | 2020-09-24 |
JP2019525950A (ja) | 2019-09-12 |
AU2017281389A1 (en) | 2019-02-07 |
US10702598B2 (en) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto |